About us

Zentraxa is an exciting new spin-out from the University of Bristol. We are commercialising a disruptive design, production and testing platform for novel peptides, and are targeting several peptide candidates in the multi-billion-dollar biotherapeutic market. 

We have unique access to the world-class infrastructure at Bristol's Centre for Synthetic Biology (BrisSynBio), including dedicated supercomputer capacity, an advanced robotics platform and world-leading high-throughput analytical platforms.

We have proprietary technology protected by patents and extensive technical knowhow, and a dedicated and experienced management team. We have developed a scalable business model around our peptide platform with rapid & significant growth potential.

Why peptides

Peptides are a class of highly bioactive molecules formed from chains of amino acids. Naturally occurring peptides control essential human functions such as growth and metabolism. They form complex shapes (as illustrated above) and trigger their effects by binding exactly to receptors on the surface of cells.

Peptides are able to form such precise shapes and binding surfaces because of the way they are formed. Each link in the chain can be composed of one of 20 different building blocks meaning that a relatively short 34 amino acid peptide could be made from 2x1044 different combinations (more than the number of atoms on planet earth)!

Application areas

There is a growing trend to use the power of peptides to treat human diseases. They can be used to treat a wide variety of conditions and are recognised as highly selective, efficacious, safe and well tolerated therapeutics. Around 140 naturally peptides are currently in clinical use or being evaluated in clinical trials.


 Excitingly however, we are only scratching the surface of what can be achieved with peptides. The total market is expected to grow from $19Bn in 2016 to $24Bn by 2020 and at Zentraxa we seek to be at the forefront of this new wave of therapeutic peptides.

Therapeutic peptides market segments

Our technology

Despite great promise, naturally derived peptides suffer from issues of stability and lifetime in the body, ease of delivery to the required site of action and unwanted off-target effects. To address these issues therapeutic peptides undergo complex chemical modifications. Zentraxa’s approach, based on precision bio-engineering provides enhanced functional changes that include, but are not limited to, increased half-life, reduced toxicity, reduced immunogenicity, and enhanced pharmacodynamic effects.

Zentraxa’s ‘Biobetters’, which are modified versions of original peptide therapeutics but with improved clinical performance, represent an opportunity to be innovative with reduced risk, minimise cost and time-to-market for the manufacturer, improved patient prognosis and convenience, and reduced overall healthcare costs. 

We harness the power of supercomputing to rationally design peptides with these improved properties. We then use high throughput robotics and analytical systems, combined with our proprietary recombinant bacterial chassis, to further refine our design and produce high quality, naturally folded peptides for customer testing.


The team


Supported by


Zentraxa is one of 15 teams selected for the prestigious Bio-Start competition - winners to be announced in July.

Contact us

EMAIL: info@zentraxa.com



University of Bristol
Biomedical Sciences Building
University Walk,
Bristol BS8 1TD.
United Kingdom